Compare AbCellera Biologics Inc (ABCL) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Synchrony Financial — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Synchrony Financial trades at $70.18 (market cap $25.40B). The key difference: Synchrony Financial is far larger — about 10.8× AbCellera Biologics Inc's market cap, and Synchrony Financial pays a 1.59% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SYF | |
|---|---|---|
Market Cap | $2.35B | $25.40B |
Sector | Health | Financials |
52-Week High | $8.12 | $88.47 |
52-Week Low | $2.78 | $63.78 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SYF trades at $77.05, up 0.94% today, with a bullish technical outlook supported by moving averages and key resistance at $78. The stock shows strong fundamentals with a P/E of 7.98, net income margin of 24.06%, and consistent earnings beats in recent quarters. Recent news highlights executive changes and partnership expansions, reinforcing growth initiatives.
The outlook remains positive with a consensus price target of $85, representing ~10% upside. Risks include interest rate sensitivity and competitive pressures, but strong analyst buy ratings (62.5%) and robust cash flow support a favorable investment case for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
